Edwards Lifesciences to collaborate with Bay Labs on heart disease detection

Edwards Lifesciences is to collaborate with Bay labs on the development of new AI-powered algorithms in Bay Labs’ EchoMD measurement and interpretation software suite. Other projects they will work on include support for ongoing clinical studies at institutions, and the integration of EchoMD algorithms into Edwards Lifesciences’ CardioCare quality care navigation platform, a platform that can help hospitals improve quality by reducing variability in echocardiography and ensure effective communication between care settings to ensure patients access to care. This has already been carried out to retrospectively analyse echocardiograms, and the collaboration believes that incorporating these and future algorithms into clinical practice could help drive quality improvement and potentially increase accurate heart disease detection.
Charles Cadieu, co-founder and CEO of Bay Labs, said: “Our partnership with Edwards Life Sciences includes multiple initiatives to deploy our artificial intelligence software with deep learning technology into clinical settings and has the potential to help patients through earlier detection of heart disease. We do believe that medtech companies are getting more comfortable with AI. One reason is that people are getting used to being assisted by AI in their everyday lives with consumer products. AI has also been demonstrated to provide clinical value and assist in clinical workflow. For example, Bay Labs EchoMD AutoEF software fully automates clip selection and calculation of left ventricular ejection fraction. EF is the single most widely used metric of cardiac function and used as the basis for many clinical decisions.”